## SURTAVI: Transaortic Valve Replacement Compared to Surgical Aortic Valve Replacement in Medium-Risk Patients

#### **Patrick W. Serruys**

Professor of Cardiology, International Center for Circulatory Health, Imperial College, London, UK Emeritus Professor of Medicine Erasmus University, Rotterdam, The Netherlands On behalf of SURTAVI Investigators Hiroki Tateishi Yoshinobu Onuma, Osama I.I. Soliman Erasmus MC, Rotterdam, The Netherlands Mohammad Abdelghani Academic MC, Amsterdam, The Netherlands



Thursday, April 30, 7:50-7:58 AM Room 104, Level 1

EU		USA	
CE mark access to multiple TAVR systems			approval termediate risk
Boston Scientific Direct Flow Edwards Jena Valve Medtronic ST. Jude SYMETIS	Lotus DFM SAPIEN-XT, -THV, -3 Jena Valve TAVI-TA/Tao CoreValve, Evolut, Evolut R, Engager-TA Portico-TF ACURATE neo+TF, TA	Edwards Medtronic	SAPIEN-XT CoreValve Evolut
Health authority requests that the manufacturer pays for the investigated device. (e.g. Italy not included in SURTAVI)		In the context of Reimbursement similar treatmer (e.g. surgical tre	at the pro rata of a nt.
26 competent authorities 70 notifying Bodies (BfArM refused to follow the adjustment of the FDA) CARDIOVASCULAR SUMMIT		FDA has agreed to adjust the inclusion criteria from 4-10 STS PROM to heart team judgement	
<b>TCTAP 2015</b>			2

#### Valve specific European registry reports

#### Medtronic CoreValve

Authors	Published year	Patients number	EuroSCORE	STS PROM
Piazza N et al.	2008	646	23.1±13.8	-
Pertronio AS et al.	2010	514	20.1(12.8-30.5)	-
Buellesfeld L et al.	2011	126	$23.43 \pm 13.80$	-
Tamburino C et al.	2011	599	$23.0 \pm 13.7$	-
Usia GP et al.	2012	181	$24.0 \pm 13.5$	$11.4 \pm 9.9$
Linke A et al.	2014	1015	$19.4 \pm 12.3$	-

#### **Edwards SAPIEN**

Authors	Published year	Patients number	EuroSCORE	STS PROM
Walther T et al.	2009	168	27±12.7	-
Thomas M et al.	2010	1038	TF 25.8±14.4 TA 29.1±16.2	-
Lefevre T et al.	2011	130	TF 33.8±14.4 TA 25.7±11.5	TF 11.8±6.8 TA 11.3±6.1
Wendler O et al.	2012	2307	TF 23.9±14.2 TA 27.6±16.1	-
Wendler O et al.	2012	2706	TF 19.9±12.0 TA 21.8±13.8	TF 8.4±7.0 TA 8.7±7.2


#### National and international registry reports


#### **Mixed Registry**


Authors	Published year	Patients number	EuroSCORE	STS PROM
Eltchaninoff H et al.	2010	244	$25.6 \pm 11.4$	$18.9 \pm 12.8$
Bosmans JM et al.	2011	328	$28 \pm 16$	-
D'Onofrio et al.	2011	504	$24 \pm 16$	11±4
Moat NE et al.	2011	870	18.5(11.7)	-
Abdel-Wahab M et al.	2011	697	$20.4 \pm 13.1$	-
Fraccaro et al.	2012	384	$24.0 \pm 15.6$	9.8±8.8
Gilard M et al.	2012	3195	21.9±14.3	$14.4 \pm 11.9$
Chieffo A et al.	2 3		SA 23.0±13.0 21.4±2.6	SAP 8.9±6.5 Core 8.1±6.2
Mario CD et al.			2±1	50 -
Sabate M et al.	<u>*</u> 2013	1416	17±11	-
Abdel-Wahab M et al.	2014	394	SAP 22.27±13.39 Core 20.61±13.93	-
Zweiker D et al.	2014	959	$21.4 \pm 13.2$	$15.4 \pm 11.0$
Maltinez-Selles M et al.	<u>*</u> 2014	261	$31.4 \pm 17.9$	-
Hamm CW et al.	2014	3876	TV 25.9 TA 24.5	-
Wenaweser P et al.	1014	697	$20.2 \pm 12.7$	8.2±7.1
D'Ascenzo F et al.	2015	674	sPAP≦40mmHg 17.2±13.1 sPAP > 40mmHg 18.5±18.9	sPAP≦40mmHg 9.4±8.4 sPAP > 40mmHg 8.7±6.7

CARDIOVASCULAR SUMMIT

### A trend in clinical European registries







# New Inclusion Criteria Following agreement with the FDA

**Version 6:** (first patient was enrolled with version 3 on 19<sup>th</sup> Jun 2012)

#### Subject must have an STS mortality risk score ≥4% and ≤10

Medtronic SURTAVI Trial. Version 6.0

**Version 8:** (now applied in 81 centers out of 82 centers; Jan 26<sup>th</sup> 2015)

 Subject must have co-morbidities such that Heart Team agrees predicted risk of operative mortality is ≥3% at 30 days

Medtronic SURTAVI Trial. Version 8.0



## **Activation and Enrollment Overview**

- 78 sites activated
  - US: 59
  - Europe: 14
  - -Canada: 5
- 1173 subjects (included before randomization)
  - US: 957
  - Europe: 174
  - Canada: 42

Data derived from "Executive committee meeting" on 8<sup>th</sup> Apr 2015



## Heart Team Review and Decision (continued)

Version 8:


- Any additional risk factors not accounted for in the STS risk calculator that may increase the level of surgical risk:
  - Heart Team should consider the following potential incremental risks:
    - Age ≥ 75
    - BNP ≥ 550pg/mL or NT proBNP ≥ 3200pg/mL
    - Prior Stroke/TIA
    - FEV1 750-1000cc
    - Home / Supplemental oxygen
    - Nocturnal Bi-level Positive Airway Pressure
    - 5-Meter Gait Speed ≥ 6 seconds
    - Severe Diastolic Dysfunction (Grade III or IV)
    - Liver Disease (Child A or B)
    - Pulmonary Hypertension (systolic pressure 60-80mmHg)
    - Frailty (e.g. BMI <21, Albumin <3.3, etc.)
    - Other risks, as deemed applicable
  - Confirm the incremental risk, as determined by the Heart Team, does not result in a risk definition higher than intermediate risk

Medtronic SURTAVI Trial. Version 8.0



Yellow indicates it was already in STS

### SURTAVI-Baseline characteristics STS risk score





Data derived from "Intelemage inteleGRID" on 7th April 2015

### SURTAVI-Baseline characteristics Potential incremental risks


Variable	Before version 8	After version 8
Age ≥ 75	86.4%	77.3% 🗸
BNP>550 pg/ml	13.8%	13.9% →
NT proBNP ≥ 3200 pg/mL	13.8%	14.1% →
Severe diastolic dysfunction	1.6%	1.8% →
Pulmonary Hypertension (systolic pressure ≥ 60 mmHg)	3.0%	2.2% 🗸
Prior Stroke/TIA	15.5%	10.8% 🗸
Home/Supplemental oxygen	2.5%	2.0% 🗸
Nocturnal Bi-PAP	4.5%	<b>6.8%</b> 个
FEV1 750-1000 cc	2.4%	1.8% 🗸
5-meter gait speed ≥ 6 seconds	26.0%	48.9% 个
Liver disease (Child A, or B)	0.4%	0.4% →
Severe Aortic Calcification	8.1%	11.5% 个



Data derived from "Intelemage inteleGRID" on 7th April 2015


## **SURTAVI Heart-Team**

Initial screening: 1616 patients approached



## **Enrollment overview**

overall



	As – Treated Population	
STS PROM estimate	TAVR Group (N = 390)	Surgical Group (N = 357)
Mean estimate - %	7.3 ± 3.0	7.5 ± 3.4
< 4% - no. (%)	33 (8.5)	40 (11.2)
4 ~ 10% - no. (%)	304 (77.9)	251 (70.3)
> 10% - no. (%)	53 (13.6)	66 (18.5)



	As – Treated Population	
STS PROM estimate	TAVR Group (N = 390)	Surgical Group (N = 357)
Mean estimate - %	7.3 ± 3.0	7.5 ± 3.4
< 4% - no. (%)	33 (8.5)	40 (11.2)
4 ~ 10% - no. (%)	304 (77.9)	251 (70.3)
> 10% - no. (%)	53 (13.6)	66 (18.5)



	As – Treated Population		
STS PROM estimate	TAVR Group (N = 390)	Surgical Group (N = 357)	
Mean estimate - %	$7.3 \pm 3.0$	$7.5 \pm 3.4$	
< 4% - no. (%)	33 (8.5)	40 (11.2)	
4 ~ 10% - no. (%)	304 (77.9)	251 (70.3)	
> 10% - no. (%)	53 (13.6)	66 (18.5)	




	As – Treated Population	
STS PROM estimate	TAVR Group (N = 390)	Surgical Group (N = 357)
Mean estimate - %	7.3 ± 3.0	7.5 ± 3.4
< 4% - no. (%)	33 (8.5)	40 (11.2)
4 ~ 10% - no. (%)	304 (77.9)	251 (70.3)
> 10% - no. (%)	53 (13.6)	66 (18.5)

Based on STS: > 80% of patients would have been SURTAVI Eligible!



#### 2-Year All-cause Mortality: CoreValve US Pivotal Trial



# Summary

- After introduction of version-8, lower objective scores (STS etc.)
- Quantification of the "incremental risk" may minimise subjectivity
- Increases of incremental risks were expected after introduction of version-8, however cardiovascular-related incremental risks (BNP, pulmonary hypertension, or prior Stroke/TIA) did decrease concertedly with STS score.
- Considering the overlap in STS and the outcome at 1year of the patients, recruited in the CoreValve US Pivotal Trial (n = 795 pts) with the patients recruited in the SURTAVI (n = 1122 pts: 650 pts for before version 8; 472 pts for after version 8, 7th Apr 2015), an interim analysis would be advisable.

